Trexon™ Monofilament Synthetic Absorbable Suture
Device Facts
| Record ID | K253530 |
|---|---|
| Device Name | Trexon™ Monofilament Synthetic Absorbable Suture |
| Applicant | Medtronic |
| Product Code | GAM · General, Plastic Surgery |
| Decision Date | May 28, 2026 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.4493 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
Trexon™ Monofilament Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, but not for use in cardiovascular and neurological surgery.
Device Story
Trexon™ Monofilament Synthetic Absorbable Suture is a sterile, absorbable surgical implant; composed of synthetic polyester (glycolide, dioxanone, trimethylene carbonate); used by trained healthcare professionals for soft tissue approximation and ligation. Device provides temporary mechanical support during healing; absorbed in vivo over 90-110 days. Available in various USP sizes (1 to 6-0), lengths, and needle configurations. Operates via physical tissue closure; no electronic or software components. Benefits include secure tissue approximation with predictable absorption profile, reducing need for secondary removal procedures. Used in clinical surgical settings.
Clinical Evidence
No clinical testing was required. Substantial equivalence was demonstrated through benchtop performance testing, including needle attachment force, suture diameter, tensile knot pull strength, and packaging integrity. Biocompatibility was established per ISO 10993 standards (cytotoxicity, sensitization, irritation, systemic toxicity, pyrogenicity, implantation). Chemical characterization and toxicological risk assessment evaluated systemic toxicity, genotoxicity, and carcinogenicity.
Technological Characteristics
Synthetic monofilament suture composed of glycolide, dioxanone, and trimethylene carbonate. USP sizes 1 to 6-0. Sterilized via ETO (ISO 11135). Packaging validated per ISO 11607. Mechanical properties tested per USP <871>, <861>, <881>. No electronic components or software.
Indications for Use
Indicated for general soft tissue approximation and/or ligation in patients requiring absorbable sutures. Contraindicated for use in cardiovascular and neurological surgery, or where extended approximation of tissue is required.
Regulatory Classification
Identification
An absorbable poly(glycolide/l-lactide) surgical suture (PGL suture) is an absorbable sterile, flexible strand as prepared and synthesized from homopolymers of glycolide and copolymers made from 90 percent glycolide and 10 percent l-lactide, and is indicated for use in soft tissue approximation. A PGL suture meets United States Pharmacopeia (U.S.P.) requirements as described in the U.S.P. “Monograph for Absorbable Surgical Sutures;” it may be monofilament or multifilament (braided) in form; it may be uncoated or coated; and it may be undyed or dyed with an FDA-approved color additive. Also, the suture may be provided with or without a standard needle attached.
Special Controls
*Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.
Predicate Devices
- Biosyn™ Monofilament Synthetic Absorbable Suture (K000037)
Reference Devices
- Monocryl™ Sutures (K964072)
Submission Summary (Full Text)
{0}
FDA U.S. FOOD & DRUG ADMINISTRATION
Build Correspondence
Convert to PDF
May 28, 2026
Medtronic
Lacee Levesque
Regulatory Affairs Manager
60 Middletown Ave.
North Haven, Connecticut 06473
Re: K253530
Trade/Device Name: Trexon™ Monofilament Synthetic Absorbable Suture
Regulation Number: 21 CFR 878.4493
Regulation Name: Absorbable Poly(Glycolide/L-Lactide) Surgical Suture
Regulatory Class: Class II
Product Code: GAM
Dated: April 30, 2026
Received: April 30, 2026
Dear Lacee Levesque:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{1}
K253530 - Lacee Levesque
Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
{2}
K253530 - Lacee Levesque
Page 3
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
TEK N. LAMICHHANE -
S
Tek N. Lamichhane, Ph.D.
Assistant Director
DHT4B: Division of Plastic and
Reconstructive Surgery Devices
OHT4: Office of Surgical and
Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{3}
| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K253530 | ? |
| Please provide the device trade name(s). | | ? |
| Trexon™ Monofilament Synthetic Absorbable Suture | | |
| Please provide your Indications for Use below. | | ? |
| Trexon™ Monofilament Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, but not for use in cardiovascular and neurological surgery. | | |
| Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? |
{4}
K253530 - Page 1 of 4
510(k) Summary
(K253530)
Date Prepared: May 28, 2026
Submitter: Covidien IIc (subsidiary of Medtronic)
60 Middletown Ave
North Haven, CT 06473
United States
Contact: Nicole Boroumand
Senior Regulatory Affairs Specialist
60 Middletown Ave
North Haven, CT 06473
United States
Telephone: (626) 375-3597
Email: Nicole.boroumand@medtronic.com
Subject Device:
Trade name: Trexon™ Monofilament Synthetic Absorbable Suture
Classification name: Suture, Absorbable, Synthetic, Polyglycolic Acid
Product Code/Registration: Product Code GAM
Regulation Number 21 CFR 878.4493
Predicate Device:
Trade/Proprietary name: Biosyn™ Monofilament Synthetic Absorbable Suture
Classification name: Suture, Absorbable, Synthetic, Polyglycolic Acid
Product Code/Registration: Product Code GAM
Regulation Number 21 CFR 878.4493
Predicate 510(k) Number: K000037
Manufacturer: Covidien IIc
15 Hampshire Street
Mansfield, MA 02048
USA
Reason for 510(k): To obtain market clearance for Trexon™ Monofilament Synthetic Absorbable Suture.
Device Description: Trexon™ Monofilament Synthetic Absorbable Suture are absorbable implants intended by the manufacturer to provide strength and support during and after surgical interventions, where soft tissue approximation and/or ligation of tissues is
{5}
K253530 - Page 2 of 4
needed. The sutures are prepared from a synthetic polyester composed of glycolide, dioxanone, and trimethylene carbonate (dyed sutures also contain D&C Violet #2) and are absorbed in approximately 90-110 Days.
Trexon™ Monofilament Synthetic Absorbable Sutures are available in USP sizes 1 through 6-0, in lengths between 18 and 96 inches, and in single-packs, multi-packs, and wide-packs with or without needles. Needle types include 3/8 circle, ½ circle, 5/8 and straight.
Intended users are healthcare professionals who have been trained in applicable surgical procedures and approaches involving sutures prior to employing this device.
## Indications for use:
Trexon™ Monofilament Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, but not for use in cardiovascular and neurological surgery.
## Substantial Equivalence:
| | Subject Device Trexon™ Monofilament Synthetic Absorbable Sutures | Predicate Device Biosyn™ Monofilament Synthetic Absorbable Sutures K000037 | Reference Device Monocryl™ Sutures K964072 |
| --- | --- | --- | --- |
| Indications For Use | Trexon™ Monofilament Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, but not for use in cardiovascular and neurological surgery. | Biosyn™ Monofilament Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, including ophthalmic surgery, but not for use in cardiovascular and neurological surgery. | MONOCRYL™ Suture is indicated for use in general soft tissue approximation and/or ligation, except for cardiovascular and neurological tissues or for microsurgery or ophthalmic surgery |
| Contraindications | This suture, being absorbable, should not be used where extended | This suture, being absorbable, should not be used where extended approximation of tissue is required. | This suture (dyed and undyed), being absorbable, should not be used where extended approximation of |
{6}
K253530 - Page 3 of 4
| | approximation of tissue is required. | | tissues under stress is required |
| --- | --- | --- | --- |
| Performance Specifications | 2-week knot pull tensile strength: approximately 50-60% of USP and EP 3-week knot pull tensile strength: 25-35% of USP and EP | Different 2-week knot pull tensile strength: minimum of 75% of EP T0 standard 3-week knot pull tensile strength: minimum of 40% of EP T0 standard | Different 2-week knot pull tensile strength: approximately 30% to 40% (dyed) or 20% to 30% (undyed) 3-week knot pull tensile strength: N/A |
| Classification | Pannel number: 79 Product code: GAM, per 21 CFR 878.4493 Absorbable poly(glycolide/l-lactide) surgical suture | Identical | N/A |
| Materials | Suture: glycolide, dioxanone, and trimethylene carbonate | Identical | N/A |
| Size and color | USP sizes 1 through 6-0. Undyed or dyed violet. | Identical | N/A |
| Configurations | Pre-cut lengths, non-needled or affixed to needles using both permanent and removable needle attachment techniques. | Identical | N/A |
| Sterilization | ETO sterilization with a minimum Sterility Assurance Level (SAL) of 10^{-6} | Identical | N/A |
| Packaging | Molded racetrack retainer inside a single | Different Figure 8 paper retainer inside a foil pouch | N/A |
{7}
K253530 - Page 4 of 4
Non-Clinical and/or Clinical Tests Summary
Performance/Non-Clinical Testing
The following performance and non-clinical testing were performed to demonstrate substantial equivalence:
| Test Description | Standard |
| --- | --- |
| Sterilization Validation | ISO 11135 |
| Stability/Shelf-Life Testing | ASTM F1980-21, ASTM F88/F88M, ISO 10993-5, USP43-NF38 2S, ASTM F88/F88M, ASTM D3078-02, F1886/F1886M-16 |
| Biocompatibility Assessment | ISO 10993-1; ISO 10993-3; ISO 10993-5; ISO 10993-6 |
| Packaging Validation | ASTM F1980-21, ISO 11607-1, ASTM F88/F88M, ASTM D4169-23E01, ASTM D3078-02, F1886/F1886M-16 |
| Benchtop Performance Testing • Needle Attachment Force • USP Suture Diameter • Tensile Knot Pull Strength • Foil Pouch Peel Strength • Visual Inspection • Suture Length • Suture Removal Force | • USP <871> • USP <861> • USP <881> • ASTM F88/F88M • ANSI/ASQ Z1.4 (for AQL sampling • USP-NF Absorbable Surgical Suture • N/A |
Biocompatibility endpoints tested: Cytotoxicity, sensitization, irritation, acute systemic toxicity, material-mediated pyrogenicity, implantation.
Chemical Characterization and Toxicological Risk assessment (CC/TRA) was used to evaluate systemic toxicity, genotoxicity, carcinogenicity, and reproductive/developmental toxicity.
No clinical testing was required.
## Conclusion:
Based upon the supporting data summarized above, Trexon™ Monofilament Synthetics Absorbable Suture is as safe and effective, and therefore substantially equivalent to the legally marketed predicate device, Biosyn™ Monofilament Synthetics Absorbable Suture (K000037).
